HERE’S WHAT INDUSTRY EXPERTS ARE SAYING

Why you should invest

Intellectual property

Our Lac Knife graphite deposit holds one of the highest concentrations of flake graphite in the world at 15% head grade that can be purified to 98%cg with basic processing. Our positive Preliminary Economic Assessment (PEA, Nov‘13) outlined positive economics: mine life of 20 years, $1.44 billion total net revenue, $890 million pre-tax undiscounted cash flow, a 36.4% pre-tax IRR with a $250 million pre-tax NPV at a 10% discount rate.

Image

Management Team

Supply conditions favor Focus Graphite. China controls the global market with over 76% of worldwide flake graphite production and with the United States producing no graphite, securing supply is critical for Industrial and technology applications

Image

Development experience

Market applications favour the company. Future demand will be driven by green technology initiatives in the Carbon Age - lithium batteries, electronics - and advanced technology-using high grade graphite in numerous applications and products.

Passion

Varius dui adipiscing, rhoncus dolor. Ut pellentesque condimentum velit quis egestas. Sed vehicula tortor lectus, vel rutrum nulla dapibus at. Morbi non iaculis lacus. Cras ornare gravida elit id pharetra. Phasellus eget lectus leo. In ac arcu sed ligula fringilla lobortis. Vivamus et elit lobortis, ultricies risus vel, volutpat orci.

Image

Regulatory strategies

Varius dui adipiscing, rhoncus dolor. Ut pellentesque condimentum velit quis egestas. Sed vehicula tortor lectus, vel rutrum nulla dapibus at. Morbi non iaculis lacus. Cras ornare gravida elit id pharetra. Phasellus eget lectus leo. In ac arcu sed ligula fringilla lobortis. Vivamus et elit lobortis, ultricies risus vel, volutpat orci.

Market trends

Simply dummy text of the printing and typesetting industry.

Meet some of the team

Eric Clemons

President and CEO

Mr. Clemons has a long history building and growing companies across multiple industries. Prior to assuming leadership of Cerebain, he served as President and Chief Operating Officer for GTC Telecom Corp, a publicly traded Nevada Corporation that operated out of Costa Mesa, CA. During his tenure, Mr. Clemons was instrumental in growing the company’s annual revenues from $500,000 per year to over $17 million per year. It was Cerebain technology, which offers a completely new way of approaching the development of an effective Alzheimer’s disease treatment that captured Mr. Clemons’ imagination, triggering his move into the life sciences arena. e-mail: clemons@cerebain.com

Wesley Tate

Chief Financial Officer

e-mail: wtate@cerebain.com Prior to joining Cerebain Biotech, Mr. Tate was the owner of Strategic Business Associates, a Tennessee-based consultancy offering business management and growth services to start-up and early-stage companies. Over the course of his career Mr. Tate has held key managerial positions at both healthcare and telecoms companies. This includes HST Global, Inc., (CFO) a development-state biotechnology company in Virginia; and Director of Operations for The Health Network, Inc., a Health and Wellness company also located in Virginia. Mr. Tate received his Bachelor of Science degree from the University of Tennessee, Knoxville, with majors in Finance and Psychology, and earned his Masters of Business Administration from the University of Tennessee, Knoxville, with concentrations in Finance and Management. He is proud to have served his country as a member of the United States Army.

Mustafa Husain M.D.

Medical and Scientific Advisor

Dr. Husain is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders. He serves as Professor of Psychiatry, Neurology & Medicine at Duke University Medical Center and is a member of Duke Institute for Brain Sciences.

Governor Scott McCallum

Strategic Business Advisor

Governor McCallum, of Wisconsin, joined Cerebain late in 2014 as a strategic advisor and business growth consultant. In addition to his work with Cerebain, he is also working on projects with the European Union Parliament, sits on a U.S. State Department/Poland Foreign Ministry Joint Commission on Innovation, and is leading an effort to use technology to match persons with Multiple Sclerosis to training and occupations in Hungary, Romania, and Poland. He also heads a project to assess and train employees for health care occupations in Poland. He is on faculty at the University of Wisconsin School of Medicine and Public Health.

Chart

Question & Answer

INTERESTED IN CEREBAIN BIOTECH?

Get in touch with Joseph Bowman at 01 800 XXX XXX to learn more about our oportunities. OR Leave your information and the best time to reach you and we will contact with you.

Information Materials

.Ipsum has been the industry's standard. Simply dummy text of the printing.

.Integer commodo lorem sed ornare eleifend. Maecenas cursus fermentum risus non consectetur. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Aliquam non pellentesque neque. Maecenas elementum mauris a sapien imperdiet hendrerit. Aenean elementum porta ante, vel sagittis lectus vestibulum sed. Nulla vitae dui nec mauris varius aliquet. Aenean nec lorem ut augue dignissim varius vulputate ac diam. Morbi ullamcorper feugiat nibh in molestie. Aliquam mollis est non iaculis mattis. Vivamus suscipit velit id consequat dapibus. Etiam blandit ante imperdiet, ullamcorper purus a, lacinia nisi. Sed imperdiet sit amet lectus in imperdiet. Proin nec hendrerit mi. Integer ornare libero et nibh placerat ultricies. Curabitur purus dolor, porta vitae gravida id, mattis a urna.


Aliquam tristique neque vitae justo congue bibendum

Industry News

Our Technology

render

Cerebain is developing a breakthrough patent-pending device that is implanted in the omentum, a protective layer of skin the protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer's Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimers Disease. Cerebain will evaluate the effect of omental stimulation at different intervals and levels of stimulation to determine the devices ability to slow, stop or reverse the progression of Alzheimers's Disease on patients. The implant procedure is minimally invasive. The company is now in the human testing stage and is seeking FDA approval.

Upcoming Events

«
»
  • No Events

Learn more about Cerebain Biotech